Sanofi Finalizes Praulent Restructuring With Regeneron
07 Abril 2020 - 3:09AM
Dow Jones News
By Giulia Petroni
Sanofi SA said late Monday that it has finalized the
restructuring of the antibody collaboration for cholesterol
treatment Praluent with Regeneron Pharmaceuticals Inc.
The French drug maker said that, starting from April 1, it will
supply the alirocumab drug outside the U.S. and Regeneron will
supply it in the U.S.
The companies, however, have entered into agreements to support
manufacturing needs in the near term.
Sanofi and Regeneron announced their intent to restructure the
antibody collaboration for Praluent in December 2019.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
April 07, 2020 01:54 ET (05:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
